ALKEM2022-10-012022-12-31 ALKEM2022-10-012022-12-31 ALKEM2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member ALKEM2022-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2022-04-01 2023-03-31 2023-02-10 2023-01-24 INR Millions Third quarter 11:00:00 13:10:00 2023-02-10 2023-02-10 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2022-10-01 2022-12-31 Unaudited Standalone 22967200000.00 607400000.00 23574600000.00 6887800000.00 2688900000.00 -383400000.00 3698200000.00 226200000.00 581400000.00 5516000000.00 19215100000.00 4359500000.00 0.00 4359500000.00 764000000.00 -293400000.00 470600000.00 0.00 3888900000.00 0.00 0.00 0.00 0.00 3888900000.00 -4100000.00 3884800000.00 0.00 0.00 239100000.00 2 32.53 32.53 0.00 0.00 32.53 32.53 1. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 9 February 2023 and subsequently approved by the Board of Directors at its meeting held on 10 February 2023. The auditors have issued an unmodified report on the financial results for the quarter and nine months ended 31 December 2022. 2. The Company has entered into a Securities Subscription Agreement and Shareholders’ Agreement dated 23 December 2022 with Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”), Eight Roads Ventures India Healthcare IV, L.P. (“Eight Roads Ventures”) and F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”) towards subscription of Compulsorily Convertible Preference Shares (‘CCPS’) by Eight Roads Ventures and F-Prime Capital in Enzene for a consideration of Rs.1,614.8 million which is equivalent to 8% of the subsidiary’s equity valuation. 3. This being the 50th year of incorporation of the Company, the Board of Directors at its meeting held on 10 February 2023 have declared a Special Dividend of Rs. 25 (Rupees Twenty five only) per equity share. In addition to the Special Dividend, the Board have also declared an interim dividend of Rs. 15 (Rupees Fifteen only) per equity share amounting to a total interim dividend of Rs. 40 (Rupees Forty only) per equity share (2000% on the face value of Rs. 2 each) for the financial year ending 31 March 2023. 4. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2022-04-01 2022-12-31 Unaudited Standalone 68165600000.00 1896900000.00 70062500000.00 19709000000.00 7081500000.00 2128100000.00 11698200000.00 646600000.00 1726900000.00 17099200000.00 60089500000.00 9973000000.00 0.00 9973000000.00 1738900000.00 -562700000.00 1176200000.00 0.00 8796800000.00 0.00 0.00 0.00 0.00 8796800000.00 -12300000.00 8784500000.00 0.00 0.00 239100000.00 2 73.57 73.57 0.00 0.00 73.57 73.57 Other expenses 5516000000.00 Other expenses 17099200000.00 -6300000.00 -18900000.00 -2200000.00 -6600000.00